In this free webinar, oncology experts will discuss what ASCO 2026 data could mean for cancer clinical trials and patient ...
These results support darovasertib plus Xalkori as a potential new standard of care if approved for HLA A*02:01-negative ...
Earlier this year, Daiichi Sankyo Global Head of Oncology Ken Keller told pharmaphorum about the company’s big year, with ...
Every year, ASCO arrives with a theme. Most quietly disappear into the background by the end of the opening session, ...
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).
At the upcoming 2026 ASCO meeting, Elizabeth A. Sakach, MD, expects the focus in metastatic breast cancer will be on the frontline integration of antibody-drug conjugates (ADCs) in triple-negative ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose ...
GEMINI-Perioperative (PeriOp) Gastric: A phase 2 study of novel agent-based combinations as PeriOp therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction (GEJ ...
Yesterday marked day one of the 2026 ASCO Genitourinary (GU) Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies that are ...
Add Yahoo as a preferred source to see more of our stories on Google. In vivo CAR-T therapies like KLN-1010 and ESOT-01 remain in early development. Credit: Krot ...
Integrated analyses show higher tumor exposure than doxorubicin and better preservation of cardiac function in randomized soft tissue sarcoma studies despite approximately 3.5-fold higher cumulative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results